J. Ferlay, I. Soerjomataram, and R. Dikshit, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer, vol.13, issue.5, pp.359-86, 2015.
DOI : 10.1002/ijc.29210

M. Engstrøm, S. Opdahl, and A. Hagen, Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients, Breast Cancer Research and Treatment, vol.100, issue.3, pp.463-73, 2013.
DOI : 10.1007/s10549-013-2647-2

E. Rakha, J. Reis-filho, and F. Baehner, Breast cancer prognostic classification in the molecular era: the role of histological grade, Breast Cancer Research, vol.55, issue.Suppl 2, 2010.
DOI : 10.1111/j.1365-2559.2009.03429.x

M. Kittaneh, A. Montero, and S. Glück, Molecular profiling for breast cancer: a comprehensive review, Biomark Cancer, vol.5, pp.61-70, 2013.

E. Luporsi, J. Bellocq, and J. Barrière, uPA/PAI-1, Oncotype DX???, MammaPrint??. Valeurs pronostique et pr??dictive pour une utilit?? clinique dans la prise en charge du cancer du sein, Bulletin du Cancer, vol.102, issue.9, pp.719-748, 2015.
DOI : 10.1016/j.bulcan.2015.05.003

URL : http://dx.doi.org/10.1016/j.bulcan.2015.05.003

P. Andreasen, L. Kjoller, L. Christensen, and M. Duffy, The urokinase-type plasminogen activator system in cancer metastasis: A review, International Journal of Cancer, vol.92, issue.1, pp.1-22, 1997.
DOI : 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z

M. Duffy, The Urokinase Plasminogen Activator System: Role in Malignancy, Current Pharmaceutical Design, vol.10, issue.1, pp.39-49, 2004.
DOI : 10.2174/1381612043453559

E. Deryugina and J. Quigley, Cell Surface Remodeling by Plasmin: A New Function for an Old Enzyme, Journal of Biomedicine and Biotechnology, vol.41, issue.7, pp.642-59, 2012.
DOI : 10.1042/BJ20110129

M. Tjwa, R. Moura, and L. Moons, Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation, Journal of Cellular and Molecular Medicine, vol.22, issue.11-12, pp.4587-95, 2009.
DOI : 10.1111/j.1582-4934.2008.00521.x

N. Beaufort, K. Plaza, and D. Utzschneider, Interdependence of kallikreinrelated peptidases in proteolytic networks, Biol Chem, vol.391, pp.581-588, 2010.

P. Carmeliet, L. Moons, and R. Lijnen, Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation, Nature Genetics, vol.139, issue.4, pp.439-483, 1997.
DOI : 10.1038/ng1297-439

D. Rifkin, Cross-talk among proteases and matrix in the control of growth factor action, Fibrinolysis and Proteolysis, vol.11, issue.1, pp.3-9, 1997.
DOI : 10.1016/S0268-9499(97)80003-3

G. Ferraris and N. Sidenius, Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction, Semin Thromb Hemost, vol.39, pp.347-55, 2013.

F. Blaisi and P. Carmeliet, uPAR: a versatile signalling orchestrator, Nature Reviews Molecular Cell Biology, vol.190, issue.12, pp.932-975, 2002.
DOI : 10.1038/nrm977

M. Jo, K. Thomas, and N. Marozkina, Dynamic Assembly of the Urokinase-type Plasminogen Activator Signaling Receptor Complex Determines the Mitogenic Activity of Urokinase-type Plasminogen Activator, Journal of Biological Chemistry, vol.280, issue.17, pp.17449-57, 2005.
DOI : 10.1074/jbc.M413141200

J. Kiyan, R. Kiyan, H. Haller, and I. Dumler, Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-??, The EMBO Journal, vol.271, issue.10, pp.1787-97, 2005.
DOI : 10.1038/sj.emboj.7600669

N. Montuori, V. Cosimato, L. Rinaldi, V. Rea, D. Alfano et al., uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors, Thrombosis and Haemostasis, vol.109, issue.2, pp.309-327, 2013.
DOI : 10.1160/TH12-08-0546

M. Conese, A. Nykjaer, and C. Petersen, alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)- dependent internalization of the urokinase receptor, The Journal of Cell Biology, vol.131, issue.6, pp.1609-1631, 1995.
DOI : 10.1083/jcb.131.6.1609

D. 'alessio, S. Blasi, and F. , The urokinase receptor as an entertainer of signal transduction, Front Biosci, vol.14, pp.4575-87, 2009.

N. Sidenius, A. Andolfo, R. Fesce, and F. Blasi, Urokinase Regulates Vitronectin Binding by Controlling Urokinase Receptor Oligomerization, Journal of Biological Chemistry, vol.277, issue.31, pp.27982-90, 2002.
DOI : 10.1074/jbc.M111736200

A. Nykjaer, C. Petersen, and B. Moller, Purified alpha2-macroglobulin receptor/LDL receptor-related protein binds plasminogen activator inhibitor type-1 complex. Evidence that the alpha2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes, J Biol Chem, vol.267, pp.14543-14549, 1992.

E. Kruithof, M. Baker, and C. Bunn, Biological and clinical aspects of plasminogen activator inhibitor type 2, Blood, vol.86, pp.4007-4031, 1995.

H. Zhou, I. Bolon, and A. Nichols, Over expression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice, Cancer Res, vol.61, pp.970-976, 2002.

K. Dano, J. Romer, and B. Nielsen, Cancer invasion and tissue remodeling-cooperation of protease systems and cell types, APMIS, vol.58, issue.1-6, pp.120-127, 1999.
DOI : 10.1111/j.1699-0463.1999.tb01534.x

M. Johnsen, L. Lund, J. Romer, K. Almholt, and K. Dano, Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation, Current Opinion in Cell Biology, vol.10, issue.5, pp.667-71, 1998.
DOI : 10.1016/S0955-0674(98)80044-6

T. Plesner, E. Ralfkiaer, and M. Wittrup, Expression of the Receptor for Urokinasetype Plasminogen Activator in Normal and Neoplastic Blood Cells and Hematopoietic Tissue, American Journal of Clinical Pathology, vol.102, issue.6, pp.835-876, 1994.
DOI : 10.1093/ajcp/102.6.835

S. Mustjoki, R. Alitalo, R. Stephens, and A. Vaheri, Blast cell surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy, Thromb Haemost, vol.81, pp.705-715, 1999.

M. Carriero, D. Vecchio, S. Franco, and P. , Vitronectin binding to urokinase receptor in human breast cancer, Clin Cancer Res, vol.3, pp.1299-308, 1997.

S. Morita, A. Sato, and H. Hayakawa, Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: Analysis by Northern blotting andin situ hybridization, International Journal of Cancer, vol.147, issue.3, pp.286-92, 1998.
DOI : 10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R

M. Hudson and L. Mcreynolds, Urokinase and the Urokinase Receptor: Association With In Vitro Invasiveness of Human Bladder Cancer Cell Lines, JNCI Journal of the National Cancer Institute, vol.89, issue.10, pp.709-726, 1997.
DOI : 10.1093/jnci/89.10.709

C. Pyke, P. Kristensen, and E. Ralfkiaer, Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas, Am J Pathol, vol.138, pp.1059-67, 1991.

D. Petro, G. Tavian, D. Copeta, A. Portolani, N. Giulini et al., Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissuetype PA messenger RNAs in human hepatocellular carcinoma, Cancer Res, vol.58, pp.2234-2243, 1998.

S. Shetty and S. Idell, A Urokinase Receptor mRNA Binding Protein???mRNA Interaction Regulates Receptor Expression and Function in Human Pleural Mesothelioma Cells, Archives of Biochemistry and Biophysics, vol.356, issue.2, pp.265-79, 1998.
DOI : 10.1006/abbi.1998.0789

T. Taniguchi, A. Kakkar, E. Tuddenham, R. Williamson, and N. Lemoine, Enhanced expression of urokinase receptor induced through the tissue factorfactor VII a pathway in human pancreatic cancer, Cancer Res, vol.58, pp.4461-4468, 1998.

M. Yamamoto, R. Sawaya, and S. Mohanam, Expression and localization of urokinase-type plasminogen activator receptor in human gliomas, Cancer Res, vol.54, pp.5016-5036, 1994.

M. Yamamoto, R. Sawaya, and S. Mohanam, Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression, Journal of Neuro-Oncology, vol.50, issue.54, pp.139-51, 1994.
DOI : 10.1007/BF01052889

M. Duffy, The Biochemistry of Metastasis, Adv Clin Chem, vol.32, pp.135-66, 1996.
DOI : 10.1016/S0065-2423(08)60427-8

M. Schmitt, N. Harbeck, and N. Brünner, Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1, Expert Review of Molecular Diagnostics, vol.11, issue.6, pp.617-651, 2011.
DOI : 10.1586/erm.11.47

T. Bugge, L. Lund, and K. Kombrinck, Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice, Oncogene, vol.16, issue.24, pp.3097-104, 1998.
DOI : 10.1038/sj.onc.1201869

K. Almholt, L. Lund, and J. Rygaard, Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice, International Journal of Cancer, vol.193, issue.4, pp.525-557, 2004.
DOI : 10.1002/ijc.20631

L. Gold, R. Schwimmer, and J. Quigley, Human plasma fibronectin as a substrate for human urokinase, Biochemical Journal, vol.262, issue.2, pp.529-563, 1989.
DOI : 10.1042/bj2620529

K. Dano, P. Andreasen, K. Grondahl-hansen, P. Kristensen, L. Nielsen et al., Plasminogen Activators, Tissue Degradation, and Cancer, Adv Cancer Res, vol.44, pp.139-266, 1985.
DOI : 10.1016/S0065-230X(08)60028-7

L. Liotta, R. Goldfarb, R. Brundage, G. Siegal, V. Terranova et al., Effect of plasminogen activator (urokinase), plasmin and thrombin on glycoprotein and collagenous components of basement membrane, Cancer Res, vol.41, pp.4629-4665, 1981.

J. Whitelock, A. Murdoch, R. Iozzo, and P. Underwood, The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin and heparanases, J Cell Biol, vol.271, pp.10079-86, 1996.

J. Kirchheimer, J. Wojta, G. Christ, and B. Binder, Proliferation of a human epidermal cell line stimulated by urokinase, FASEB J, vol.1, pp.125-133, 1987.

J. Plouet, F. Moro, and S. Bertagnolli, Extracellular Cleavage of the Vascular Endothelial Growth Factor 189-Amino Acid Form by Urokinase Is Required for Its Mitogenic Effect, Journal of Biological Chemistry, vol.272, issue.20, pp.13390-13396, 1997.
DOI : 10.1074/jbc.272.20.13390

W. Mars, R. Zarnegar, and G. Michalopoulos, Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA, Am J Pathol, vol.143, pp.949-58, 1993.

M. Cross and L. Claesson-welsh, FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition, Trends in Pharmacological Sciences, vol.22, issue.4, pp.201-208, 2001.
DOI : 10.1016/S0165-6147(00)01676-X

H. Yu and T. Rohan, Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression, Journal of the National Cancer Institute, vol.92, issue.18, pp.1472-89, 2000.
DOI : 10.1093/jnci/92.18.1472

L. Trusolino and P. Comoglio, SCATTER-FACTOR AND SEMAPHORIN RECEPTORS: CELL SIGNALLING FOR INVASIVE GROWTH, Nature Reviews Cancer, vol.2, issue.4, pp.289-300, 2002.
DOI : 10.1038/nrc779

L. Devy, S. Blacher, and C. Grignet-debrus, The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent, The FASEB Journal, vol.16, issue.2, pp.147-54, 2002.
DOI : 10.1096/fj.01-0552com

M. Jo, K. Thomas, A. Somloyo, A. Somlyo, and S. Gonias, Cooperativity between the Ras-ERK and Rho-Rho Kinase Pathways in Urokinase-type Plasminogen Activator-stimulated Cell Migration, Journal of Biological Chemistry, vol.277, issue.14, pp.12479-85, 2002.
DOI : 10.1074/jbc.M111147200

G. Deng, S. Curriden, S. Wang, S. Rosenberg, and D. Loskutoff, Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?, The Journal of Cell Biology, vol.134, issue.6, pp.1563-71, 1996.
DOI : 10.1083/jcb.134.6.1563

Z. Ma, D. Webb, J. M. Gonias, and S. , Endogenously produced urokinase-type plasminogen activator is a major determinant of 1196 Duffy: uPA and PAI-I in Breast Cancer the basal level activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells, J Cell Sci, vol.114, pp.3387-96, 2001.

P. Pakneshan, M. Szyf, R. Farias-eisner, and S. Rabbani, Reversal of the Hypomethylation Status of Urokinase (uPA) Promoter Blocks Breast Cancer Growth and Metastasis, Journal of Biological Chemistry, vol.279, issue.30, pp.31735-31779, 2004.
DOI : 10.1074/jbc.M401669200

J. Jovanovic, J. Rønneberg, J. Tost, and V. Kristensen, The epigenetics of breast cancer, Molecular Oncology, vol.12, issue.3, pp.242-54, 2010.
DOI : 10.1016/j.molonc.2010.04.002

R. Stephens, N. Brunner, F. Janicke, and M. Schmitt, The urokinase plasminogen activator system as a target for prognostic studies in breast cancer, Breast Cancer Research and Treatment, vol.22, issue.8670, pp.99-111, 1998.
DOI : 10.1023/A:1006115218786

M. Sternlicht, A. Dunning, and D. Moore, Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 Expression, Cancer Epidemiology Biomarkers & Prevention, vol.15, issue.11, pp.2107-2121, 2006.
DOI : 10.1158/1055-9965.EPI-06-0351

F. Janicke, A. Prechtl, and C. Thomssen, Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1, JNCI Journal of the National Cancer Institute, vol.93, issue.12, pp.913-933, 2001.
DOI : 10.1093/jnci/93.12.913

A. Prechtl, N. Harbeck, and C. Thomssen, Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node negative breast cancer, Int J Biol Markers, vol.15, pp.73-81, 2000.

N. Harbeck, R. Kates, and K. Gauger, Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer, Thrombosis and Haemostasis, vol.91, pp.450-456, 2004.
DOI : 10.1160/TH03-12-0798

E. Luporsi, J. Bellocq, and J. Barrière, uPA/PAI-1, Oncotype DX???, MammaPrint?? Prognosis and predictive values for clinical utility in breast cancer management, Oncologie, vol.136, issue.Suppl1, pp.196-206, 2014.
DOI : 10.1007/s10269-014-2379-x

M. Hery, T. Delozier, and A. Ramaioli, Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?, The Breast, vol.11, issue.5, pp.442-450, 2002.
DOI : 10.1054/brst.2002.0462

É. Luporsi, F. André, and J. Bellocq, Rapport 2009 sur l?????tat des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX??? et MammaPrint?? dans la prise en charge du cancer du sein, Oncologie, vol.12, issue.2, pp.158-63, 2010.
DOI : 10.1007/s10269-009-1851-5

J. Ciccolini, Editorial [Hot Topic: Targeted Therapy, Targeted Dosing and Targeted Delivery in Oncology: Where Do We Stand?], Current Topics in Medicinal Chemistry, vol.12, issue.15, p.1638, 2012.
DOI : 10.2174/156802612803531379

F. André, J. Ciccolini, and J. Spano, Personalized medicine in oncology: where have we come from and where are we going?, Pharmacogenomics, vol.14, issue.8, pp.931-940, 2013.
DOI : 10.2217/pgs.13.79

N. Hartung, S. Mollard, and D. Barbolosi, Mathematical Modeling of Tumor Growth and Metastatic Spreading: Validation in Tumor-Bearing Mice, Cancer Research, vol.74, issue.22, pp.6397-407, 2014.
DOI : 10.1158/0008-5472.CAN-14-0721

URL : https://hal.archives-ouvertes.fr/hal-01107681

S. Benzekry, A. Tracz, M. Mastri, R. Corbelli, D. Barbolosi et al., Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach, Cancer Research, vol.76, issue.3, pp.535-582, 2016.
DOI : 10.1158/0008-5472.CAN-15-1389

URL : https://hal.archives-ouvertes.fr/hal-01222046

M. Look, W. Van-putten, and M. Duffy, Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients, JNCI Journal of the National Cancer Institute, vol.94, issue.2, pp.116-144, 2002.
DOI : 10.1093/jnci/94.2.116

N. Harbeck, R. Kates, and M. Schmitt, Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination, Journal of Clinical Oncology, vol.20, issue.4, pp.1000-1009, 2002.
DOI : 10.1200/JCO.2002.20.4.1000

N. Harbeck, U. Alt, and A. Krüger, Prognostic impact of proteolytic factors (uPA, PAI-1, cathepsins B, D, L) in primary breast cancer reflects effects of adjuvant systemic therapy, Clin Cancer Res, vol.7, pp.2757-64, 2001.

A. Goldhirsch, J. Glick, and R. Gelber, Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer, Journal of Clinical Oncology, vol.19, issue.18, pp.3817-3844, 2001.
DOI : 10.1200/JCO.2001.19.18.3817

F. Jänicke, A. Prechtl, and C. Thomssen, Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1, JNCI Journal of the National Cancer Institute, vol.93, issue.12, pp.913-933, 2001.
DOI : 10.1093/jnci/93.12.913

N. Harbeck, P. Dettmar, and C. Thomssen, Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up, British Journal of Cancer, vol.80, issue.3-4, pp.419-445, 1999.
DOI : 10.1038/sj.bjc.6690373

F. Cardoso, L. Van-'t-veer, E. Rutgers, S. Loi, S. Mook et al., Clinical Application of the 70-Gene Profile: The MINDACT Trial, Journal of Clinical Oncology, vol.26, issue.5, pp.729-764, 2008.
DOI : 10.1200/JCO.2007.14.3222

M. Schmitt, O. Wilhelm, and U. Reuning, The urokinase plasminogen activator system as a novel target for tumour therapy, Fibrinolysis and Proteolysis, vol.14, issue.2-3, pp.114-146, 2000.
DOI : 10.1054/fipr.2000.0079

B. Muehlenweg, S. Sperl, and V. Magdolen, Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumors, Expert Opin Biol Ther, vol.1, issue.4, pp.683-91, 2001.